XNASEMBC
Market cap1.13bUSD
Jan 10, Last price
19.48USD
1D
-3.80%
1Q
51.95%
IPO
-36.13%
Name
Embecta Corp
Chart & Performance
P/E
14.46
P/S
1.01
EPS
1.35
Div Yield, %
3.05%
Shrs. gr., 5y
—
Rev. gr., 5y
0.25%
Revenues
1.12b
+0.21%
Net income
78m
+11.22%
CFO
36m
-47.27%
Dividend
Aug 27, 20240.15 USD/sh
Earnings
Feb 07, 2025
Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | |
| Income | ||||||
Revenues | 1,123,100 0.21% | 1,120,800 -0.77% | 1,129,500 -3.05% | |||
Cost of revenue | 466,700 | 456,100 | 421,500 | |||
Unusual Expense (Income) | ||||||
NOPBT | 656,400 | 664,700 | 708,000 | |||
NOPBT Margin | 58.45% | 59.31% | 62.68% | |||
Operating Taxes | (34,100) | 35,300 | 33,000 | |||
Tax Rate | 5.31% | 4.66% | ||||
NOPAT | 690,500 | 629,400 | 675,000 | |||
Net income | 78,300 11.22% | 70,400 -68.52% | 223,600 -46.09% | |||
Dividends | (34,500) | (34,400) | (8,600) | |||
Dividend yield | 3.96% | 0.52% | ||||
Proceeds from repurchase of equity | (3,600) | |||||
BB yield | 0.41% | |||||
| Debt | ||||||
Debt current | 12,900 | 13,100 | 13,100 | |||
Long-term debt | 1,629,100 | 1,675,900 | 1,666,900 | |||
Deferred revenue | (46,100) | |||||
Other long-term liabilities | 42,200 | 41,800 | 46,100 | |||
Net debt | 1,374,500 | 1,362,500 | 1,444,600 | |||
| Cash flow | ||||||
Cash from operating activities | 35,700 | 67,700 | 412,200 | |||
CAPEX | (15,800) | (26,500) | (24,000) | |||
Cash from investing activities | (15,800) | (26,500) | (24,000) | |||
Cash from financing activities | (73,400) | (48,700) | (48,000) | |||
FCF | 680,000 | 766,000 | 679,400 | |||
| Balance | ||||||
Cash | 267,500 | 326,500 | 330,900 | |||
Long term investments | (95,500) | |||||
Excess cash | 211,345 | 270,460 | 178,925 | |||
Stockholders' equity | (790,800) | (849,600) | (901,400) | |||
Invested Capital | 1,703,100 | 1,723,600 | 1,626,600 | |||
ROIC | 40.30% | 37.57% | 60.77% | |||
ROCE | 71.02% | 76.05% | 91.79% | |||
| EV | ||||||
Common stock shares outstanding | 57,758 | 57,055 | ||||
Price | 14.10 -6.31% | 15.05 -47.72% | 28.79 | |||
Market cap | 869,258 -47.08% | 1,642,623 | ||||
EV | 2,231,758 | 3,087,223 | ||||
EBITDA | 692,600 | 697,300 | 739,700 | |||
EV/EBITDA | 3.20 | 4.17 | ||||
Interest | 112,300 | 107,000 | 46,200 | |||
Interest/NOPBT | 17.11% | 16.10% | 6.53% | |||